FDA Brief

Warning letters Food

FDA warning letter to

H.E.A.L. Marketplace

High riskIssued May 12, 2023Posted May 23, 2023Division of Human and Animal Food Operations East III

H.E.A.L. Marketplace sold four herbal products as unapproved new drugs with disease-treatment claims, FDA says.

What happened

In March 2023, FDA reviewed www.healmarketplace.com and www.ladyofherbs.com, which redirect or link to www.healmarketplace.shop, and found the company takes orders there for four products. The websites claimed the products treat diseases such as epilepsy, colds, flu, high blood pressure, and insomnia. FDA determined the products are unapproved new drugs and are misbranded because they lack adequate directions for use.

What FDA found

  1. The website claims make the products drugs intended to cure, mitigate, treat, or prevent disease.

    section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The products are new drugs because they are not generally recognized as safe and effective for their claimed uses and lack FDA approval.

    sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. §§ 321(p), 331(d), 355(a)]
  3. The products are misbranded because they fail to bear adequate directions for use by a layperson.

    section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. Introducing or delivering the misbranded drugs into interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the letter of the specific steps taken to address the violations and prevent recurrence, with supporting documentation. If corrective actions cannot be completed in that time, the company must state the reason and the time within which it will do so.

Who should pay attention

  • online sellers of herbal tinctures and tonics
  • companies making disease-treatment claims on product websites
  • brands and retailers offering supplements with drug-like claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk